Innovation all for the patients

CHUGAI

Roche A member of the Roche group

Galderma's Announcement Regarding Nemolizumab (FDA Approval for the Treatment of Prurigo Nodularis)

TOKYO, August 14, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release on August 13 that the U.S. Food and Drug Administration (FDA) has approved the humanized anti-human IL-31 receptor A monoclonal antibody Nemluvio® (generic name: nemolizumab) for the treatment of adults with prurigo nodularis (PN). Nemolizumab was created by Chugai, and its clinical development outside Japan is being conducted by Galderma.

Please refer to the link below for details of the Galderma's press release:
Galderma receives U.S. FDA approval for Nemluvio® (nemolizumab) for adult patients living with prurigo nodularis
https://www.galderma.com/news/galderma-receives-us-fda-approval-nemluvior-nemolizumab-adult-patients-living-prurigo

###

CHUGAI PHARMACEUTICAL CO., LTD. Corporate Communications Dept.
1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku Tokyo, 103-8324 Japan
Media Relations Group TEL:+81-(0)3-3273-0881 E-mail:pr@chugai-pharm.co.jp
Investor Relations Group TEL:+81-(0)3-3273-0554 E-mail:ir@chugai-pharm.co.jp